INGREZZA
Live / Applied — Fourth extension granted (statement of use) (as of 05 Feb 2026)
What this means for you
Not registered yet, but its 11 Nov 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97673813
- Mark type
- Design + words
- Filed
- 11 Nov 2022
- Published for opposition
- 10 Oct 2023
- Attorney of record
- Allison Strickland Ricketts
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for schizophrenia, adjunctive treatment of schizophrenia, schizoaffective disorder, bipolar disorder, bipolar mania, DiGeorge syndrome, Lesch-Nyhan syndrome, and movement disorders, namely, Myoclonus, Levodopa induced dyskinesia, dyskinetic cerebral palsy, dystonia, and tics; Pharmaceutical preparations for the treatment of neurological, central nervous system, and movement diseases and disorders
Owner
- Neurocrine Biosciences, Inc., San Diego, CA, US
- Neurocrine Biosciences, Inc., San Diego, CA, US
Prosecution history
- 05 Feb 2026 — SOU EXTENSION 4 GRANTED
- 01 Dec 2025 — SOU EXTENSION 4 FILED
- 02 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Oct 2025 — SOU EXTENSION 3 GRANTED
- 20 May 2025 — SOU EXTENSION 3 FILED
- 21 May 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Mar 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 20 Mar 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 20 Mar 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 05 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Dec 2024 — SOU EXTENSION 2 GRANTED
- 25 Nov 2024 — SOU EXTENSION 2 FILED
- 25 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 10 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED